Clinical Studies Gain Pace as Pharmaceutical Industry Helps to Wage War on Diabetes Pandemic
Pharmaceutical companies across the globe are stepping up the number of clinical studies as diagnosed cases of diabetes reach pandemic levels.
London-based clinical research specialist MeDiNova alone currently has two studies underway in a bid to further improve treatments for this debilitating illness which has tightened its grip on the UK population.
Research remains one of the most vital tools in the fight against the disease — a treatable killer condition which is arguably one of the fastest growing illnesses within the UK.
The statistics for diabetes are frightening. Latest figures from Diabetes UK reveal 387 million people worldwide are living with the disease, including 3.2 million in the UK. An estimated one in 10 have the type 2 strain and almost half of all type 2 sufferers across the world are unaware of their condition.
Until recently, the type 2 strain only affected adults — most commonly, 40–59-year-olds. The first cases in children did not emerge until the year 2000.
But research by the World Health Organisation shows it is now growing increasingly common in children, with obesity, lack of physical activity and general unhealthy lifestyles among the contributing factors.
In addition to diabetes itself, sufferers are at risk of developing further complications, including blindness, amputation and stroke.
Since insulin was discovered in 1921, continued research and the development of new treatments have helped save millions of lives. This research is as imperative today. During the next two decades the number of people with diabetes is expected to rise to 592 million. Research is one of the most powerful weapons in the quest to stem the pandemic and change the future of diabetes.
As one of the top five dedicated research centres in the UK, MeDiNova’s role in the fight against diabetes is pivotal. With regular trials for diabetes the company is now seeking volunteers for two new studies.
The trials are open at MeDiNova’s two centres — the North London Clinical Studies Centre in Northwood and the South London Clinical Studies Centre in Sidcup.
Kumar Muthlagappan, Chief Executive of MeDiNova, said: “Diabetes is one of the largest and most fearsome threats to humanity. It is true that the type 2 strain is largely preventable. Even so, there are millions of people across the world with it, including in the UK.
“The development of new treatments is crucial if we are ever going to win the war against diabetes. Each and every one of our volunteers plays a vital role in this battle — not for themselves and others around them today who may also be affected, but for their children, and their children’s children, who will continue to be blighted by this killer without ongoing research.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance